Rev Neurol France
-
Review Guideline
[Experts' recommendations for stroke management in intensive care: intracranial hypertension].
This article aims to describe the arguments underlying the experts' recommendations for management of stroke patients in the intensive unit, focusing on intracranial hypertension. This article describes the pathophysiology, diagnostic methods and therapeutic options for intracranial hypertension after stroke, including medical and surgical management.
-
Review Guideline
[Treatment of arterial and venous brain ischemia. Experts' recommendations: stroke management in the intensive care unit].
With thrombolysis, intravenous alteplase (0.9 mg/kg body weight, maximum 90 mg), with 10% of the dose given as a bolus followed by a 60-minute infusion, is recommended within 4.5 hours of onset of ischemic stroke. When indicated, intravenous thrombolysis must be initiated as soon as possible. It is possible to use intravenous alteplase in patients with seizures at stroke onset, if the neurological deficit is related to acute cerebral ischemia. ⋯ The optimal administration route (local or intravenous), thrombolytic agent (urokinase or alteplase) and dose are unknown. There is currently no recommendation with regard to local thrombolytic therapy in patients with dural sinus thrombosis. Urgent blood transfusions are recommended to reduce hemoglobin S to <30% in patients with sickle cell disease and acute ischemic stroke.
-
Review Guideline
[Specific treatment for intracerebral hemorrhage. Experts' recommendations: stroke management in the intensive care unit].
Spontaneous intracerebral hemorrhages represent from 10 to 15% of strokes. They can be defined by the eruption of arterial blood within the cerebral parenchyma. Clinical signs are not specific and the diagnosis can only be made using brain imaging techniques (CT or magnetic resonance imaging). Management of intracerebral hemorrhage combines general measures (neurovascular intensive care unit, treatment of high blood pressure and of neurotoxic factors) with more specific measures including correction of coagulation abnormalities and, in some cases, neurosurgical treatment.
-
Criteria for the clinical diagnosis of Alzheimer's disease (AD) were established in 1984, and they needed to be updated and revised, in vue of the scientific knowledge acquired over the last decades. ⋯ In the revised criteria, a conceptual distinction is made between AD pathophysiological processes and clinically observable syndromes. The core clinical criteria of the recommendations regarding MCI due to AD and AD dementia are intended to guide diagnosis in the clinical setting whereas the recommendations of the preclinical AD workgroup are intended purely for research purposes and do not have any clinical implications. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.